No stone left unturned: Challenges encountered during recruitment of women with advanced ovarian cancer for a phase I study

被引:5
作者
Albrecht, Tara A. [1 ]
Taylor, Ann Gill [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
关键词
Clinical trial research; Cancer; Recruitment; Research methodology; CLINICAL-TRIAL; MEDICINE USE; COMPLEMENTARY; ONCOLOGY; BARRIERS; MASSAGE; THERAPY;
D O I
10.1016/j.apnr.2013.05.003
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The recruitment and accrual of participants for cancer clinical trial research is often challenging. Chronic low accrual rates negatively influence the findings and generalizability that can be drawn from the available pool of research. There is a need for further evidence regarding both unsuccessful and successful approaches and useful strategies that investigators have used to counter common recruitment challenges. During recruitment for an intervention study examining the safety, efficacy, and feasibility of a potentially novel supportive therapy, a variety of steps were taken to avoid and subsequently overcome potential and real recruitment challenges the investigators faced. In this article the authors provide an overview of common recruitment challenges as well as the actual challenges encountered, procedures and strategies implemented to counter these challenges, while investigating the combined intervention of flaxseed oil, fasting, caffeine, and exercise in women with recurrent or multi-drug resistant stage HI or IV ovarian cancer. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 50 条
  • [41] Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study
    Bruzzone, M.
    Centurioni, M. G.
    Giglione, P.
    Gualco, M.
    Merlo, D. F.
    Miglietta, L.
    Cosso, M.
    Giannelli, F.
    Cristoforoni, P.
    Ferrarini, M.
    ONCOLOGY, 2011, 80 (3-4) : 238 - 246
  • [42] A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Ullenhag, Gustav J.
    Rossmann, Eva
    Liljefors, Maria
    PLOS ONE, 2015, 10 (04):
  • [43] A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Bullock, Karen E.
    Petros, William P.
    Younis, Islam
    Uronis, Hope E.
    Morse, Michael A.
    Blobe, Gerard C.
    Zafar, S. Yousuf
    Gockerman, Jon P.
    Lager, Joanne J.
    Truax, Roxanne
    Meadows, Kellen L.
    Howard, Leigh A.
    O'Neill, Margot M.
    Broadwater, Gloria
    Hurwitz, Herbert I.
    Bendell, Johanna C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 465 - 474
  • [44] Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer
    Jiang, Yixing
    Mackley, Heath B.
    Kimchi, Eric T.
    Zhu, Junjia
    Gusani, Niraj
    Kaifi, Jussuf
    Staveley-O'Carroll, Kevin F.
    Belani, Chandra P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 205 - 210
  • [45] Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study
    Francois, E.
    Bennouna, J.
    Chamorey, E.
    Etienne-Grimaldi, M. C.
    Renee, N.
    Senellart, H.
    Michel, C.
    Follana, P.
    Mari, V.
    Douillard, J. Y.
    Milano, G.
    CHEMOTHERAPY, 2012, 58 (05) : 371 - 380
  • [46] Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
    Ramasubbaiah, R.
    Perkins, S. M.
    Schilder, J.
    Whalen, C.
    Johnson, C. S.
    Callahan, M.
    Jones, T.
    Sutton, G.
    Matei, D.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (03) : 499 - 504
  • [47] Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer
    Hirao, M
    Fujitani, K
    Tsujinaka, T
    DISEASES OF THE ESOPHAGUS, 2004, 17 (03) : 247 - 250
  • [48] Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
    Spano, Jean-Philippe
    Moore, Malcolm J.
    Pithavala, Yazdi K.
    Ricart, Alejandro D.
    Kim, Sinil
    Rixe, Olivier
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1531 - 1539
  • [49] A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
    Ryan, CW
    Vokes, EE
    Vogelzang, NJ
    Janisch, L
    Kobayashi, K
    Ratain, MJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (01) : 1 - 5
  • [50] Phase I Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel Chemotherapy for Locally Advanced Cervical Carcinoma in Japanese Women
    Umayahara, Kenji
    Takeshima, Nobuhiro
    Nose, Takayuki
    Fujiwara, Kiyoshi
    Sugiyama, Yuko
    Utsugi, Kuniko
    Yamashita, Takashi
    Takizawa, Ken
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (04) : 723 - 727